Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Lirilumab

Known as: IPH2102 
A fully humanized monoclonal antibody against killer-cell immunoglobulin-like receptors (KIR), with potential antineoplastic activity. Upon… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Mechanisms of resistance to immune‐modulating cancer treatments are poorly understood. Using a novel cohort of patients with head… Expand
2018
2018
Purpose Anti-KIR monoclonal antibodies (mAbs) can enhance the antitumor responses of natural killer (NK) cells. We evaluated the… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
2018
2018
Micro‐Abstract: We report the results of a prospective trial of lirilumab in patients with myelodysplastic syndrome (MDS). A… Expand
  • table 1
  • table 2
  • table 3
Review
2017
Review
2017
Background Inhibitory Killer Immunoglobulin-like Receptors (KIR) negatively regulate Natural Killer (NK) cell-mediated killing of… Expand
2016
2016
### O1 Combinatorial CD8+ and PD-L1+ cell densities correlate with response and improved survival in non-small cell lung cancer… Expand
Highly Cited
2015
Highly Cited
2015
Despite recent treatment improvements, multiple myeloma remains an incurable disease. Since antibody-dependent cell-mediated… Expand
  • table 1
Highly Cited
2014
Highly Cited
2014
Natural killer (NK) cells mediate antilymphoma activity by spontaneous cytotoxicity and antibody-dependent cell-mediated… Expand
Review
2013
Review
2013
Natural killer (NK) cells are critical innate immune lymphocytes capable of destroying virally infected or cancerous cells… Expand
  • table 1
2013
2013
Natural Killer cells (NK cells) are lymphocytes able to recognize and kill tumors for which the expression of Major… Expand
2013
2013
TPS3110 Background: Immune checkpoint blockade represents a novel form of cancer immunotherapy. Killer cell immunoglobulin-like… Expand